Valuation: Autolus Therapeutics plc

Market Cap 572M 494M 464M 422M 794M 54.72B 807M 5.44B 2.13B 27.4B 2.15B 2.1B 91.06B P/E 2026 *
-2.79x
P/E 2027 * -3.51x
Enterprise Value 515M 445M 418M 380M 715M 49.27B 727M 4.9B 1.92B 24.67B 1.93B 1.89B 81.99B EV / Sales 2026 *
3.44x
EV / Sales 2027 * 3.32x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+6.28%
1 week+10.14%
Current month+53.02%
1 month+58.33%
3 months+26.67%
6 months+50.99%
Current year+14.57%
1 week 2.02
Extreme 2.02
2.43
1 month 1.38
Extreme 1.38
2.43
Current year 1.18
Extreme 1.175
2.43
1 year 1.18
Extreme 1.175
2.43
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
6/29/26 A Free

Director

79,167 0.0477%
3/18/26 A Other

Director

310,000 0.1866%
3/18/26 A Other

General Counsel

780,818 0.4700%
Change 5-day change 1-year change 3-year change Capi.($)
+6.28%+10.14%+21.28%-22.45% 572M
+0.57%+0.13%+40.98%+1.55% 80.23B
-1.02%-0.51%-2.54%+28.91% 50.64B
+1.65%-4.13%+10.41%+165.05% 46.87B
-1.39%+0.10%-50.39%-50.07% 46.34B
-0.08%+1.32%+54.41%-19.75% 31B
+2.03%+9.20%+132.50%-38.53% 25.28B
+1.74%+0.53%+43.89%+90.30% 24.36B
+1.65%-2.00%-6.43%+191.59% 20.81B
+3.59%+1.33%+62.42%+119.85% 16.08B
Average +1.52%+0.46%+30.65%+46.64% 34.22B
Weighted average by Cap. +0.58%+0.53%+24.25%+39.50%

Financials

2026 *2027 *
Net sales 150M 129M 122M 111M 208M 14.32B 211M 1.42B 557M 7.17B 562M 550M 23.83B 194M 167M 157M 143M 269M 18.51B 273M 1.84B 720M 9.27B 727M 711M 30.8B
Net income -213M -184M -173M -157M -296M -20.37B -300M -2.03B -792M -10.2B -800M -782M -33.89B -181M -157M -147M -134M -252M -17.33B -256M -1.72B -674M -8.68B -681M -666M -28.84B
Net Debt -57M -49.23M -46.26M -42.07M -79.1M -5.45B -80.4M -542M -212M -2.73B -214M -209M -9.07B 69.6M 60.11M 56.49M 51.37M 96.59M 6.66B 98.18M 662M 259M 3.33B 261M 256M 11.08B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
17/08/26 $2.280 +6.05% 718,353
14/08/26 $2.150 -3.15% 2,395,470
13/08/26 $2.220 +4.72% 2,242,456
12/08/26 $2.120 -9.01% 4,059,386
11/08/26 $2.330 +12.56% 7,686,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.150USD
Average target price
8.725USD
Spread / Average Target
+305.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock